Neutralizing antibodies for the treatment of COVID-19

Shibo Jiang; Xiujuan Zhang; Yang Yang; Peter J Hotez; Lanying Du

doi:10.1038/s41551-020-00660-2

Neutralizing antibodies for the treatment of COVID-19

Nat Biomed Eng. 2020 Dec;4(12):1134-1139. doi: 10.1038/s41551-020-00660-2.

Authors

Shibo Jiang^{1

2}, Xiujuan Zhang¹, Yang Yang^{3

4}, Peter J Hotez⁵, Lanying Du⁶

Affiliations

¹ Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA.
² Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China.
³ Howard Hughes Medical Institute, Yale University, New Haven, CT, USA.
⁴ Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA.
⁵ Departments of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA.
⁶ Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA. ldu@nybc.org.

Abstract

More clinical trial data are needed to determine whether sera from COVID-19-convalescent patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent COVID-19 or reduce the severity of the disease in high-risk populations.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antibodies, Neutralizing / immunology*
Antibodies, Neutralizing / therapeutic use*
COVID-19 / immunology*
COVID-19 / virology
COVID-19 Drug Treatment*
Humans
Pandemics / prevention & control
SARS-CoV-2 / immunology
Serum / immunology

Substances

Antibodies, Neutralizing

Abstract

Publication types

MeSH terms

Substances

Grants and funding